Clinical Trials Browser

Lymphoma, B-Cell, Marginal Zone

NCT04877821 2026-04-02

NeoSACT

Phase 2 Completed

29 enrolled

Breast

Triple Negative Breast Neoplasms

NCT06797635 2026-03-13

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

Phase 2 Recruiting

372 enrolled

Breast

Breast Neoplasms

NCT06829199 2026-02-19

MK-5890-003

Phase 2 Withdrawn

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06291064 2026-02-17

TARMAC

Phase 2 Recruiting

85 enrolled

Breast

Triple Negative Breast Neoplasms

NCT07320508 2026-01-21

EIC-SNACC

Phase 2 Recruiting

100 enrolled

Carcinoma, Adenoid Cystic

NCT04770272 2026-01-12

neoMono

Phase 2 Terminated

442 enrolled 42 charts

Breast

Triple Negative Breast Neoplasms

NCT04872985 2026-01-06

Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast Cancer

Phase 2 Active not recruiting

140 enrolled

Breast

Breast Neoplasms

NCT06107673 2025-12-11

Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC）

Phase 2 Recruiting

144 enrolled

Breast

Breast Neoplasms

NCT04214626 2025-11-19

R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma

Phase 2 Completed

60 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT07016399 2025-10-30

Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC

Phase 2 Recruiting

51 enrolled

Breast

Triple Negative Breast Neoplasms

NCT03515798 2025-09-12

PELICAN

Phase 2 Active not recruiting

52 enrolled

Breast

Inflammatory Breast Neoplasms

NCT04138719 2025-09-11

Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer

Phase 2 Recruiting

520 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05900206 2025-09-02

ARIADNE

Phase 2 Recruiting

370 enrolled

Breast

Breast Neoplasms

NCT05582499 2025-08-22

FASCINATE-N

Phase 2 Recruiting

716 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06500208 2025-06-26

Neoadjuvant Adebrelimab and Chemotherapy in High-rish ER+/HER2- BC

Phase 2 Recruiting

48 enrolled

Breast

Breast Neoplasms

NCT06860529 2025-06-23

Serplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast Cancer

Phase 2 Recruiting

357 enrolled

Breast

HR+/HER2- Breast Cancer

NCT01630083 2025-06-15

FAST

Phase 2 Completed

252 enrolled

Gastrointestinal

CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction

NCT06964906 2025-05-11

NeoHunter

Phase 2 Recruiting

140 enrolled

Breast

Breast Neoplasms

NCT04668365 2025-04-25

Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma

Phase 2 Suspended

59 enrolled

Lymphoid

Congenital Abnormalities, Lymphoma, Large B-Cell, Diffuse

Clinical Trials

VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma

NeoSACT

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

MK-5890-003

TARMAC

EIC-SNACC

neoMono

Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast Cancer

Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC）

R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma

Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC

PELICAN

Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer

ARIADNE

FASCINATE-N

Neoadjuvant Adebrelimab and Chemotherapy in High-rish ER+/HER2- BC

Serplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast Cancer

FAST

NeoHunter

Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma